HOLD study (Home care Obstructive Lung Disease): natural history of patients with advanced COPD

Daniel Gainza Miranda1*, Eva María Sanz Peces1, Alberto Alonso Babarro2, María Concepción Prados Sánchez3 and María Varela Cerdeira4

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is the fourth cause of death in western countries. Its final stage has clearly been forgotten by medical research in recent years. There exists consensus regarding the need to integrate palliative care in assisting these patients, but the difficulty in establishing a prognosis for the disease, establishing limits for life support measures, the lack of information about the disease’s natural course and ignorance as to the most effective health-care structure for these patients’ palliative treatment may be responsible for their late inclusion or non-inclusion in specific programmes. The main purpose of this work is to find out the natural background of patients with stage IV COPD and the main prognostic factors that influence these patients’ survival.

Methods/design: Prospective observational study of a home patient cohort with stage IV COPD sent from Neumology consultations and Palliative Care Unit in La Paz Hospital in Madrid and Primary Care Health Centres in the area to the palliative care home support team. The goal is to study socio-demographic variables, prognosis, nutritional status, use of health resources, perceived quality of life, functionality, main symptomatology, use and effectiveness of opioids, adherence to treatment, prognostic information regarding the disease, information given by professionals, advance directives, social backup requirements and overburden level of the main caregiver.

Discussion: The HOLD study is a project aimed at finding out the prognostic factors and evolution of the disease COPD in its most advanced stage. The final goal is to improve the health and quality of life, in a personalised, integral way up to end of life and explore and foster communication with patients, as well as their participation and collaboration in decision-taking. The HOLD study can help us better understand what these patients’ real palliative and care needs are, in order to more efficiently organise their treatment at end of life.

Keywords: COPD, Palliative care, Homecare, End of life

Background

Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth cause of death in western countries [1, 2], and it is, among the main ones, the one that has most increased in recent years [1]. The advanced stages of the disease are characterised by significant morbidity. The high frequency of symptoms, functional deterioration and the large number of exacerbations lead to major deterioration in patients’ quality of life, to a high rate of hospitalisations and, in general, to a significant increase in care and treatment costs [3, 4].

The final stage of progressive, incurable diseases have been ignored by medical research until recent years. In general, patients in more advanced stages have been excluded from research work. However, only a proper description of the final stage of these diseases can let us better evaluate patients’ needs and the care and treatment they should receive [5]. The results of the SUPPORT study [6] showed the significant deficiencies in the care of these ill people which comprise both the treatment of symptoms and the consideration of patients’ advance directives.

There is consensus regarding the need to integrate palliative care in attending to patients with COPD. In recent years, practically all scientific organisations that include professionals involved in attending these patients...
and different health-care institutions have made major efforts to try to divulge the need to apply the principles of palliative care to these patients [7–11]. The main problem in implementing palliative care programmes for patients with advanced COPD lies in establishing appropriate prognostic criteria. Some prognostic indexes have been created to help in selection processes. The BODE index [12] is the most widespread [13, 14]. However, even patients with very high values on the BODE index may survive for years. The patient cohort with Advanced Chronic Respiratory Disease in the SUPPORT study [15] showed how patients with worse self-perception of their state of health survived less. Subsequently, other works have shown how ratings obtained by questionnaires on health-related quality of life, both general and specific, are correlated with survival [16, 17]. The difficulty in estimating the survival of patients with advanced COPD may mean that they receive sub-optimal treatment.

Despite showing a comparable frequency of symptoms and, in general, similar needs, when end-of-life care received by the patients with lung cancer is compared with that of advanced COPD sufferers, favourable results are always obtained for oncological patients [18]. In these studies, patients with advanced COPD show: worse health and social care, worse diagnostic and prognostic information, worse symptomatological control, less participation in clinical decision-taking and greater use of aggressive measures to increase survival [15, 19–21]. In a study carried out by Heyland and cols. [22], patients with advanced-stage COPD reported, as high-priority needs, good symptomatic control, not being a burden for their family, receiving appropriate information which includes benefits and risks of the treatment, and having access to a doctor to ask questions regarding their disease.

In short, the difficulty in establish a prognosis, the difficulty in limiting advanced life-support measures and the lack of information about the disease's natural course can be responsible for the these patients’ late inclusion or exclusion in palliative care programmes. In recent years, authors have recommended, in order to improve this situation, including palliative care as part of the standard team responsible for monitoring patients in advanced stages, in such a way that a palliative approach to the disease starts early, regardless of their prognosis [23].

Continuity of care is a key element in offering proper health care to patients with advanced diseases [24]. A single team, especially if it is hospital-based, cannot respond to patient’s needs under any circumstance. For this reason, coordination is essential with different care resources. Home care allows attention to be given directly to advanced-COPD patients [25] whose functional deterioration prevents them from leaving home and attending consultations. It would therefore be a key factor for ensuring continuity of care.

There barely exist works on the most effective health structure for attending to end-of-life for these patients [24], nor on the natural background of patients with advanced COPD. These kinds of studies can provide us with information about symptomatic burden, quality of life and real needs of health resources for these patients. This information would let us develop more effective health structures and improve the care that these patients receive, offering them and their families more realistic expectations as the disease progresses and they approach the moment of death.

The main goal of the study is to find out the natural background of stage-IV COPD patients, from when the advanced disease obliges them to stay at home, prospectively evaluating the evolution of symptoms, quality of life and the use of health resources in the final stage of the illness.

The specific goals of this work are:

1. Find out the main prognostic parameters in these patients survival and in the evolution of their quality of life
2. Assess the level of information to patients with COPD and to their families, the percentage of patients with advance directive documents and the level of information given by professionals and included in their reports
3. Find out the evolution of COPD patients functionality, describe the most important symptoms, paying special attention to dyspnoea, as well as its level of control and co-morbidity
4. Evaluate use of health resources in advanced stages of COPD patients monitored at home
5. Evaluate perceived quality of life and its evolution in the advanced stage of the COPD at home
6. Estimate the use of opioids in standard clinical practice for treating dyspnoea and their effectiveness in controlling dyspnoea
7. Assess the level of therapeutic compliance and inhalant techniques and the use of home oxygen therapy
8. Find out the main caregiver’s social support needs and level of over-burden

Methods
Design
Prospective observational study of a stage-IV COPD patient cohort immobilised at home.

Participants and recruitment
The study will include patients sent to the Palliative Home Care Support Team (PHCST) from the Neumology Service in La Paz Hospital, from the Palliative Care Unit, or from Primary Health Care diagnosed with stage...
IV COPD who are going to be monitored at home and who fit the criteria for inclusion, exclusion and withdrawal (Table 1).

Data collection
The information will be collected during programmed visits to the patients’ home, by PHCST researchers.

In the initial visit, apart from checking that the patient complies with the criteria for inclusion and exclusion, and the signature of informed consent, information will be gathered on the patient’s variables (listed below). Monitoring visits will be carried out quarterly up to a 2-year maximum (Fig. 1).

Variables
During the different programmed home visits, the following variables will be collected by the research team:

Socio-demographic variables
Age, sex, education level, labour situation, family unit, relationship with main caregiver.

Survival variables
– Survival time: this will be calculated as from the registration date of the disease’s stage IV diagnosis and date of death. Survival will also be calculated as from the date of inclusion in the study.
– Place of death (Home/Palliative Care Unit/Hospital Ward/Residence/Emergency Room).

Personal background
Smoking, packets/year, age when smoking started, cardiac insufficiency, high blood pressure, diabetes, depression, anxiety disorder, flu and pneumococcal vaccine, Pseudomonas aerogynose isolation.

Prognostic variables
– Charlson comorbidity index [26]: absence of comorbidity is considered: 0–1 points; low comorbidity: 2 points; and high: > 3 points. Since monitoring will be less than 5 years this will not be corrected by age.
– BODE Index [12]: calculations will collect indexes of body mass, last FEV1 upon discharge, Modified Medical Research Council dyspnoea scale and the 6-min walk distance at the end of consultations. Scored from 0 to 10 points.
– Surprise question: formulated as “would you be surprised if this patient dies the next year? YES/NO”. The care team will make this question after the patient’s first home evaluation [27].
– Palliative Prognostic Score: prognostic scale that divides patients into three risk groups: A (>70 % probabilities of survival at 30 days) if the score is between 0–5.5; B (30-70 % survival at 30 days) if the score is between 5.6 and 11; and C (probability less than 30 % at 30 days) if the score is between 11.1 and 17.5 [28].
– Nutritional state: this will be obtained via three variables. The body mass index, albumin obtained by blood analysis and Mini Nutritional Assessment (MNA): a nutritional screening and assessment instrument for the elder population [29], validated in Spanish [30].

Variables to determine the use of health resources and social support needs in the final stage
– Telephone calls: Made to the PHCST, Primary care health team (PCHT), emergency calls, and tele-assistance. Caregivers will be asked about calls made since the previous visit.
– Home visits: Carried out by the PHCTS (collected by care/research team),
– Visits made by primary care doctor in homes and health centres (asking the patient and/or carer and checking in the computer programme AP-Madrid visits registered by PCHT).
– Hospitalisations/hospital emergencies: collected by reports of admissions by hospital services. This will also register the number of days hospitalised.
– Admissions to Palliative Care Units/Residences: this will register the number of days admitted up to death. It will be recorded by telephoning the centre.

Variables to “Evaluate perceived quality of life”
– St. George’s questionnaire regarding health-related quality of life, validated in Spanish [31]: This will be

| Table 1 Criteria for selecting patients |
|----------------------------------------|
| Criteria for inclusion | Criteria for exclusion | Criteria for withdrawal |
| • Over 18 years old | • Severe cognitive deterioration or severe mental illness | • Suffering from lung cancer, of recent appearance during monitoring |
| • Clinical diagnosis of stage-IV COPD according to GOLD 2007 guidelines | • Diagnosed with lung cancer or cystic fibrosis | • Change of habitual residence outside the Northern Community of Madrid Care Directorate |
| • Functional deterioration that hampers monitoring in external consultations or PPS below 70 | • Impossibility of maintaining home care due to absence of main caregiver | • Admission to a Palliative Care Unit |
| | • Not fluent in Spanish language | • Patient decides to abandon the study |
checked after being carried out to evaluate its full implementation. Score variations of 4 points are considered clinically significant.

- Questionnaire regarding health-related quality of life: COPD Assessment Test (CAT) [32]. Score from 0 to 40. It divides patients into low-impact levels (<10 points), medium-impact (10 to 20 points), high-impact (more than 20 points) or very high (more than 30 points). Self-fulfilment will be supervised by the health team. Variations of 2 points in the score are considered clinically significant.

Variables to “Evaluate the functionality of COPD patients”

- Palliative Performance Scale (PPS) [33]: Functional assessment scale based on the Karnofsky scale. It scores from 0 to 100 % where 0 % is the patient’s death and 100 % means a healthy patient able to walk around.
- Barthel index (BI) [34]: The BI is an ordinal scale used to measure performance in activities of daily living (ADL). It aims to assign each patient a score of their level of dependence to carry out a
series of basic activities. It uses ten variables

describing ADL and mobility. The values assigned
to each activity depend on the time used to carry
them out and need for help to do so \cite{8, 10}.

- International Physical Activity Questionnaire, short
version \cite{35}: This provides information about time
used when walking, activities of moderate and
vigorous intensity and in sedentary activities.
Physical activity is described in Metabolic Equivalent
Tasks (METs), where an equivalent metabolic task is
equal to the energy expended while resting, and are
expressed in METs minutes/week. The IPAQ
considers moderate-intensity activities to be those of
3–6 METs and vigorous to those greater than 6
METs. The questionnaire also classifies physical
activity in three levels: lowers, moderate and high.
Finally, the questionnaire includes an additional
indicator of sedentary activity that does not add to
the score, and which corresponds to time sitting
down, measured separately for working days and
weekends.

A drop in functionality will be evaluated by unit of
time in order to evaluate the linearity of the loss and its
relation with survival

**Variables to “evaluate the most important symptoms, level
of control and co-morbidity”**

- Edmonton Symptom Assessment System (ESAS) in
its validated Spanish version \cite{36}: list of 10
numerical scales from 1 to 10, which evaluate the
average intensity of 10 symptoms at a certain time.
The patient is requested to indicate the number that
best represents the intensity of each symptom. If the
patient were unable to indicate it correctly, he or
she will be asked about each symptom and to qualify
it as zero, slight, moderate, severe or very severe,
assigning for each of these answers a score of: 0
nothing, 2 for slight, 5 for moderate, 7 severe and 10
very severe.

- Dyspnoea Scale of the British Medical Research
Council (MRC) \cite{37}: this evaluates the level of
dyspnoea from 0 to 4 (level 0: the dyspnoea only
begins with maximum effort; up to level 4: the
dyspnoea exists while resting and prevents the
patient from leaving his or her home). This will be
evaluated by asking the patient during a clinical
interview.

- The Hospital, Anxiety and Depression Scale \cite{38}:
This consists of 14 items. It measures mood with
two scales, one for anxiety and another for
depression. According to the score obtained it is
divided into non-case of anxiety/depression (0–7
points), doubtful case of anxiety/depression \cite{8–10}
and case of anxiety/depression if a score above 11
points is obtained.

Number of exacerbations: this will register the number
of exacerbations attended during the patient’s monitor-
ing by the PHCST and exacerbations that have required
hospitalisation will be noted.

**Variables to “Evaluate the use of opiates in standard
clinical practice to treat dyspnoea and their effectiveness in
controlling dyspnoea”**

- Use of opioids: use yes/no, date prescribed,
professional who prescribes their use.

- Effectiveness: The use of opioids will be considered
effective in controlling dyspnoea if it decreases in
the ESAS by at least 2 points with the response
remaining for at least 3 days. A check-up will be
carried out on the third day of the opiate’s
prescription to ask about the dyspnoea. Time of
treatment with opioids will also be evaluated,
including date of treatment withdrawal and reason
for doing so.

**Variables to “Evaluate the level of therapeutic compliance
and the inhalant technique and home use of oxygen
therapy”**

- Morinsky-Green Questionnaire validated in Spanish
\cite{39}: This evaluates patients’ attitudes regarding the
treatment. Patients who respond correctly to the
four questions it comprised will be qualified as
compliant. An inadequate response qualifies the
patient as non-compliant.

- Inhaler type and inhalant technical: This will register
the type of inhalers that the patient uses and the
inhalant technique will be evaluated, classifying it
as correct or incorrect according to the
recommendations of the Spanish Neumology and
Thoracic Surgery Society (SEPAR), for the use of
inhalers \cite{38}.

- Variables relating to oxygen therapy: This will
record the number of hours of oxygen therapy the
patient has used the previous day, the number of
litres per minute determined from neumology and
the number of litres per minute administered by the
patient’s concentrator, checking the flow meter
during the visit. It will also evaluate the increase in
oxygen requirements by time unit with the aim of
evaluating reality of loss and its relationship with
survival. Use of non-invasive ventilation mechanics
and number of hours of ventilation will be also
evaluated.
Variables to “Evaluate the level of information to COPD patients and their families”

a) Information given by the professional: This will register the patient’s reports or record. The patient will be considered as:
- Informed by the professional of the diagnosis: if the reports show that the patient has been explained that he/she suffers from COPD and its level of severity.
- Informed by the professional of the prognosis: if the reports show that the limitation of life expectancy has been explained, conditioned by the base disease.
- Partially informed: If there exists registered information as regards diagnosis and prognosis but it is incomplete (understanding complete to mean as described in the previous point).
- Not informed: if it is shown that information has not been passed on to the patient as regards the diagnosis or prognosis. Apart from background, this will also register or by contacting the responsible professional the reason for non-information (not requirement of information from the patient, difficulties in professional/patient communication, pact of silence, other).
- Not referred: the patient’s clinical record or reports do not register whether information has been given to the patient regarding the diagnosis and/or prognosis.

b) Information perceived by the patient: During the clinical interview, the patient’s knowledge will be evaluated as regards their diagnosis and prognosis, classifying the patient as:
- Expert: We will consider the patient to be an expert of the diagnosis if on being asked which disease they are suffering, the patient refers to: “COPD”, “chronic bronchitis”, “bronchitis”, “lung disease”, “bronchial disease”, “chronic lung disease”. They must also express its chronic, irreversible nature: “It is chronic”, “it is incurable”, “it is irreversible”, “it is forever”, “it’s for life”, “it has no solution”. We will also consider the patient to be an expert on the prognosis if they consider that their life expectancy is limited as a consequence of their disease.
- Partially expert: During the interview, the patient does not know their diagnosis or prognosis or they partially know the information as regards diagnosis or prognosis.
- Non-expert: The patient does not know either the diagnosis or the prognosis.
- Not explored: Not approached during the interview by the team. The reason will be given (information not required by the patient, difficulties in the professional/patient communication, pact of silence, other).

Variables to “Evaluate the main carer’s social support needs and level of over-burden” registering the following variables

- Gijón abbreviated and modified scale of socio-family evaluation [40]: This evaluates 3 items: family situation, relationships and social contacts and social network support.
- Zarit Burden interview short version [41]: questionnaire of 7 items where the caregiver assigns a frequency corresponding to a score of 1 to 5. If the sum of the scores is greater than or equal to 17 it would indicate caregiver overburden.

Calculation of sample size and data analysis
It is estimated that in the Community of Madrid (the population is around 6,400,000 inhabitants), every year 500 COPD patients enter the final stage of the disease. Coverage by the team of professional researchers is for a population of around 1,000,000, so it is estimated that at most up to 77 patients/year could be included and with a forecast to include approximately 70 % of these patients from the area covered by the ESAPD and a 2-year period of recruitment. 108 patients would be included, which would guarantee adequate representation of this population. It is calculated that losses could mean 10-20 % of these patients, so the final sample size is considered to be between 80 and 100 patients.

The information included in the data-collection book will be recorded in a local database. This database will have the necessary protection measures and it will only
be accessible by the project researchers. Prior to the statistical analysis, an analysis of the quality of the data collected will be carried out to purge any possible transcription errors.

**Statistical analysis**
Most of the goals will be met with descriptive statistics, summarising the quantitative variables by means of average, standard deviation and minimum and maximum values. For asymmetric distributions, the median will be used as a centralisation measure and percentiles 25 and 75 as measures of dispersion. For categorical variables, their absolute frequency and distribution of frequencies will be expressed. Evaluation of survival will be carried out by taking into account the date when home monitoring began and date of death (or departure from the study), using a Cox proportional hazards model to examine the independent effect of the prognostic variables studied.

The statistical programme SPSS version 21.0 will be used.

**Discussion**
The HOLD study is a project focused on finding out the factors prognostic and the evolution of the disease COPD in its most advanced stage. In recent years, other works have described the advanced stage of other organic insufficiencies and neuro-degenerative diseases [42, 43]. We need to have the best scientific evidence to respond to the needs of patients suffering from advanced diseases [5]. The final goal should be to improve health and quality of life in a personalised, integral way until end of life. Respiratory diseases represent the second cause as regards the type of cases attended in hospitals, accumulating 11.6 % of discharges (only behind those of the circulatory system), they are the fourth cause of death and are also among the first four diagnoses in global costs for the Spanish health system, representing the largest use of health resources and with the greatest intensity in the elderly population, as is the case of most of these patients and in the final stages of the disease [44]. In economic terms, it is estimated that at outpatient level, COPD represents an expense of 528 million euros a year. By patient and severity, a patient with serious COPD generated an expense of 3,335 euros a year, a patient with moderate COPD 2,275 euros/year and a patient with slight COPD 1,650 euros/year [44]. The proposed investigation would provide better knowledge on achieving the system’s sustainability through rational use of all available resources, and a health care that goes from primary care and specialised attention to home and palliative care.

A very significant goal of this study is to find out and encourage communication with patients, as well as their participation and collaboration in decision-taking. Involving patients in decision-taking is not only a right but also improves therapeutic results by avoiding treatment considered to be disproportionate and improving patients’ quality of life [45–47].

COPD has a major impact on quality of life due to dyspnoea, respiratory insufficiency, exacerbations and hospitalisations, leading to a reduction in productive activities, social relationships, significant dependence and social isolation. Our study seeks to contribute new knowledge regarding these patients’ needs and possible strategies to address them. In particular, the aim is to explore the use of opioids in these patients’ dyspnoea [48].

In conclusion, the study of advanced COPD's natural background can help us to better understand what are the real assistance and palliative needs of these patients at end of life, with the aim of more efficiently organising their care at end of life.

**Limitations of the study**
Our study has some possible limitations in design as regards the inclusion of participants and the parameters evaluated.

Firstly, the selection of patients mainly on the reference Neumology Services and the sample obtained may not be representative of the patients immobilised at home with a diagnosis of advanced (stage IV) COPD. It could therefore be necessary to use a recruitment strategy that also takes into account primary care doctors to access most of the patients in the area with these characteristics.

Secondly, as regards the variables evaluated, the registration dates of the diagnosis may not be totally exact, as they are based mainly on clinical registrations, and it is known to be a disease that is under-diagnosed and under-registered. However, most clinical information will be obtained directly from the patient or from the clinical record and the close, constant monitoring of these patients by the research team.

Thirdly, there may be losses in monitoring for reasons of institutionalisation, admittance or change of home. However, we think that the relationship of the ESAPD not only with the patient but with his or her close family environment, would allow this information to be recovered.

**Ethical aspects**
Patients will be requested, freely and voluntarily, to give informed consent in writing if they are interested in taking part in the study, after reading the information sheet and clarifying any possible doubt they have about the study.

The project will be carried out in accordance with the basic principles of the Declaration of Helsinki and according to the legal regulations in effect (Royal Decree
As regards data confidentiality, the study will comply with the terms laid down in the effective legislation: Organic Act 157/1999 of 13 December on Personal Data Protection (Official State Gazette number 298 of 14 December 1999), dissociating the data that could identify patients.

Competing interests
The hold study has a grant from the fund for aid to health research from the economy Ministry of the Spanish Government for an amount of 12,600 euros. (Project code PI14/01271).
The authors declare they have no other conflicts of interest.

Authors’ contributions
DGM, AAB and CPS designed the study. DGM will direct data collection, analysis and divulgation of the results. DGM, AAB, CPS and MVC contributed to writing the manuscript and data collection. All the authors have read and approved the final document.

Authors’ information
DGM is a doctor of the ESAPD in the Northern Community of Madrid care directorate. Master in Palliative Care from the UAM and an expert in palliative care from the University of Valladolid. ESP is a nurse of the ESAPD in the Northern Community of Madrid care directorate. She is also a teacher and coordinator of specific palliative care courses in Madrid Health Department.

AAB is head doctor at the Palliative Care Unit in La Paz. Also subdirector of the Palliative Care Master at the Autonomous University of Madrid. CPS is section head doctor of the Neumology Service of La Paz University Hospital. She is also a lecturer at the Autonomous University of Madrid in the Medical Faculty.

MVC is a doctor in the hospital support team at the Ramón y Cajal Hospital in Madrid. He is also a teacher in the Palliative Care Master at the Autonomous University of Madrid.

Acknowledgements
The authors would like to thank Elena Polentinos Sánchez and Ricardo Rodríguez Barrientos from the primary care research support unit for their contribution in advising on the draft of the manuscript, advice in seeking financing and the final draft of the text.

The authors declare they have no other conflicts of interest.

Competing interests
The Authors would like to thank Elena Polentinos Sánchez and Ricardo Rodríguez Barrientos from the primary care research support unit for their contribution in advising on the draft of the manuscript, advice in seeking financing and the final draft of the text.

The authors declare they have no other conflicts of interest.

References
1. WHO. World Health Report. Geneva: World Health Organisation; 2003. Available at: http://who.int/whr/2003/en/
2. Regidor E, Güetírez-Fisc J, Calle ME, Otero AA. Patrón de mortalidad en España 1998. Med Clin (Barc). 2002;118:13–5.
3. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest. 2001;119:344–52.
4. Niewoehner DE. Outpatient management of severe COPD. N Engl J Med. 2010;362:1407–16.
5. Callahan D. Death and the research imperative. N Engl J Med. 2000;342:654–6.
6. The SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). JAMA. 1995;274:1591–8.
7. Lanken PN, Terry PB, DeLisser HM, Falty BF, Hansen-Flaschen J, Heffner JE, et al. An Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses. American Thoracic Society Documents. Am J Respir Crit Care Med. 2008;177:912–22.
8. Plan Nacional de Cuidados Paliativos. Bases para su desarrollo. Madrid: Ministerio de Sanidad y Consumo; 2001.
9. Ministerio de Sanidad y Consumo. Estrategia en Cuidados Paliativos del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo; 2007.
10. Davies E, Higginson IJ. WHO. Informe técnico: hechos sólidos en cuidados paliativos. Madrid: Ministerio de Sanidad y Consumo; 2004.
11. Cuervo Pinna MA, Prados C, Alonso Babarro A. Cuidados paliativos en pacientes con enfermedades respiratorias crónicas en fase avanzada. Medicina Paliativa. 2010;17(4):226–33.
12. Celi BR, Cote CG, Marin JM, Casanova C, Monteles de Oca M, Mendez RA, et al. The body mass index, airflow obstruction, dyspnea, an exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.
13. Soler-Cataluña JJ, Martínez-García MA, Román P, Salcedo F, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–31.
14. Puhan MA, García-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374:704–11.
15. Claessens MT, Lynn J, Zhong Z, Desbiens NA, Phillips RS, Wu AW, et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. Study to understand prognoses and preferences for outcomes and risks of treatments. J Am Geriatr Soc. 2000;48(Suppl):S146–53.
16. García S, Clara E. Causes of death and prediction of mortality in COPD. Arch Bronconeumol. 2010 Jul;46(7):342–6.
17. Domingo-Salvany A, Lamarca R, Ferrer M, García-Aymerich J, Alonso J, Férez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:60–5.
18. Burt J, Shipman C, Richardson A, Ream E, Addington-Hall J. The experiences of older adults in the community dying from cancer and non-cancer causes: a national survey of bereaved relatives. Age Ageing. 2010;39:86–91.
19. Bausewein C, Booth S, Gyssel M, Kühnback R, Haberland B, Higginson IJ. Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. J Palliat Med. 2010;13(9):1109–18.
20. Chou WC, Lai YT, Huang YC, Chang CL, Wu WS, Hung YS. Comparing end-of-life care for hospitalized patients with chronic obstructive pulmonary disease and lung cancer in Taiwan. J Palliat Care. 2013;29(1):129–35.
21. Romem A, Tom SE, Beauchene M, Babington L, Scharf SM, Romem A. Pain management at the end of life: A comparative study of cancer, dementia and chronic obstructive pulmonary disease patients. Palliat Med. 2015;29(5):464–9.
22. Heyland DK, Dodick P, Rocker G, Groll D, Gafni A, Pichora D, et al. Canadian Researchers End-of-Life Network (CARENET): What matters most in end-of-life care: perceptions of seriously ill patients and their family members. CMAJ. 2006;174:627–33.
23. Bourke SJ, Peel ET. Palliative care of chronic progressive lung disease. CMAJ. 2006;174:627–33.
24. Boland J, Martin J, Wells AU, Ross JR. Palliative care for people with non-malignant lung disease: summary of current evidence and future direction. Palliat Med. 2013;27(9):811–22.
25. Terry P. Hospice and Pulmonary Medicine. Chest. 2002;121(1):11–2.
26. Charlson M, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
27. DeSalvo KB, Fan VS, McDonell MB, Fihn SD. Predicting mortality and healthcare utilization: a single question. Health Serv Res. 2005;40:1234–46.
28. Maltoni M, Nanni O, Pirovano M, Scarpi E, Indelli M, Martini C, et al. Successful Validation of the Palliative Prognostic Score in Terminally III Cancer Patients. J Pain Man. 1999;17(4):240–7.
29. Guigoz Y, Vellas B, Garry PJ. Mini Nutritional Assessment: a practical assessment tool for grading the nutritional state of elderly patients: Facts and reseach. Gerontology. 1994;15:59.
30. Salá V, Bolíbar I, Muñoz M, Sacristán V. Un nuevo instrumento para la valoración nutricional en geriatría: El Mini Nutritional Assessment (MNA). Rev Gerontol. 1996;6:319–28.
31. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;Suppl B:25–31. discussion 33–7.
32. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–54.
33. Anderson F, Downing GM, y cols Hill J. Palliative Performance Scale (PPS): a new tool. J Palliat Care. 1996;12:5–11.
34. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md Med J. 1965;14:61–5.
35. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire:12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95.
36. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.
37. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ. 1960:166.
38. Zigmond A, Snaith P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;6:361–70.
39. Brinkman-Stoppelenburg A, Rietjens JAC, van der Heide A. The effects of advance care planning on end-of-life care: A systematic review. Palliat Med. 2014;28(8):1000–25.
40. Schrijvers D et al. ESMO Clinical Practice Guidelines on palliative care: advanced care planning. Ann Oncol. 2014;25(Supplement 3):iii138–42.
41. López-Saca JM, Centeno C. Opioids prescription for symptoms relief and the impact on respiratory function: updated evidence. Curr Opin Support Palliat Care. 2014;8:383–90.